Budesonide/Formoterol Teva Pharma B.V.

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Laadi alla Infovoldik (PIL)
30-01-2017
Laadi alla Toote omadused (SPC)
30-01-2017
Laadi alla Avaliku hindamisaruande (PAR)
30-01-2017

Toimeaine:

Budesonide, formoterol

Saadav alates:

Teva Pharma B.V.

ATC kood:

R03AK07

INN (Rahvusvaheline Nimetus):

budesonide, formoterol fumarate dihydrate

Terapeutiline rühm:

Drugs for obstructive airway diseases,

Terapeutiline ala:

Asthma

Näidustused:

Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

Toote kokkuvõte:

Revision: 1

Volitamisolek:

Withdrawn

Loa andmise kuupäev:

2014-11-19

Infovoldik

                                40
B. PACKAGE LEAFLET
Medicinal product no longer authorised
41
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. 160 MICROGRAMS/4.5 MICROGRAMS,
INHALATION POWDER
(budesonide/formoterol fumarate dihydrate)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Budesonide/Formoterol Teva Pharma B.V. is and what it is used for
(page 3)
2.
What you need to know before you use Budesonide/Formoterol Teva Pharma
B.V. (page 5)
3.
How to use Budesonide/Formoterol Teva Pharma B.V. (page 9)
4.
Possible side effects (page 18)
5.
How to store Budesonide/Formoterol Teva Pharma B.V. (page 21)
6.
Contents of the pack and other information (page 22)
1.
WHAT BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS AND WHAT IT IS USED FOR
Budesonide/Formoterol Teva Pharma B.V. contains two different active
substances: budesonide and
formoterol fumarate dihydrate.
•
Budesonide belongs to a group of medicines called
‘corticosteroids’ also known as ‘steroids’. It works
by reducing and preventing swelling and inflammation in your lungs and
helps you to breathe more
easily.
•
Formoterol fumarate dihydrate belongs to a group of medicines called
‘long-acting β
2
adrenoceptor
agonists’ or ‘bronchodilators’. It works by relaxing the muscles
in your airways. This will help to open
the airways and help you to breathe more easily.
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS INDICATED FOR USE IN ADULTS
18 YEARS OF AGE AND OLDER
ONLY.
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS NOT IND
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms
inhalation powder.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose that leaves the mouthpiece of the
Spiromax) contains 160 micrograms of
budesonide and 4.5 micrograms of formoterol fumarate dihydrate.
This is equivalent to a metered dose of 200 micrograms budesonide and
6 micrograms of formoterol
fumarate dihydrate.
Excipient(s) with known effect:
Each dose contains approximately 5 milligrams of lactose (as
monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder.
White powder.
White inhaler with a semi-transparent wine red mouthpiece cover.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years
of age and older only.
Asthma
_ _
Budesonide/Formoterol Teva Pharma B.V. is indicated in the regular
treatment of asthma, where use of a
combination (inhaled corticosteroid and long-acting β
2
adrenoceptor agonist) is appropriate:
-in patients not adequately controlled with inhaled corticosteroids
and “as needed” inhaled short-acting β
2
adrenoceptor agonists.
or
-in patients already adequately controlled on both inhaled
corticosteroids and long-acting β
2
adrenoceptor
agonists.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years
of age and older only.
Budesonide/Formoterol Teva Pharma B.V. is not indicated for use in
children, 12 years of age and younger
or adolescents, 13 to 17 years of age.
Medicinal product no longer authorised
3
Posology
_Asthma _
_ _
Budesonide/Formoterol Teva Pharma B.V. is not intended for the initial
management of asthma.
Budesonide/Formoterol Teva Pharma B.V. is not an appropriate treatment
for the adult patient with only
mild asthma who is not adequately controlled with an inhaled
corticosteroid and 
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 30-01-2017
Toote omadused Toote omadused bulgaaria 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 30-01-2017
Infovoldik Infovoldik hispaania 30-01-2017
Toote omadused Toote omadused hispaania 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 30-01-2017
Infovoldik Infovoldik tšehhi 30-01-2017
Toote omadused Toote omadused tšehhi 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 30-01-2017
Infovoldik Infovoldik taani 30-01-2017
Toote omadused Toote omadused taani 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande taani 30-01-2017
Infovoldik Infovoldik saksa 30-01-2017
Toote omadused Toote omadused saksa 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande saksa 30-01-2017
Infovoldik Infovoldik eesti 30-01-2017
Toote omadused Toote omadused eesti 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande eesti 30-01-2017
Infovoldik Infovoldik kreeka 30-01-2017
Toote omadused Toote omadused kreeka 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 30-01-2017
Infovoldik Infovoldik prantsuse 30-01-2017
Toote omadused Toote omadused prantsuse 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 30-01-2017
Infovoldik Infovoldik itaalia 30-01-2017
Toote omadused Toote omadused itaalia 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 30-01-2017
Infovoldik Infovoldik läti 30-01-2017
Toote omadused Toote omadused läti 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande läti 30-01-2017
Infovoldik Infovoldik leedu 30-01-2017
Toote omadused Toote omadused leedu 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande leedu 30-01-2017
Infovoldik Infovoldik ungari 30-01-2017
Toote omadused Toote omadused ungari 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande ungari 30-01-2017
Infovoldik Infovoldik malta 30-01-2017
Toote omadused Toote omadused malta 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande malta 30-01-2017
Infovoldik Infovoldik hollandi 30-01-2017
Toote omadused Toote omadused hollandi 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 30-01-2017
Infovoldik Infovoldik poola 30-01-2017
Toote omadused Toote omadused poola 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande poola 30-01-2017
Infovoldik Infovoldik portugali 30-01-2017
Toote omadused Toote omadused portugali 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande portugali 30-01-2017
Infovoldik Infovoldik rumeenia 30-01-2017
Toote omadused Toote omadused rumeenia 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 30-01-2017
Infovoldik Infovoldik slovaki 30-01-2017
Toote omadused Toote omadused slovaki 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 30-01-2017
Infovoldik Infovoldik sloveeni 30-01-2017
Toote omadused Toote omadused sloveeni 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 30-01-2017
Infovoldik Infovoldik soome 30-01-2017
Toote omadused Toote omadused soome 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande soome 30-01-2017
Infovoldik Infovoldik rootsi 30-01-2017
Toote omadused Toote omadused rootsi 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 30-01-2017
Infovoldik Infovoldik norra 30-01-2017
Toote omadused Toote omadused norra 30-01-2017
Infovoldik Infovoldik islandi 30-01-2017
Toote omadused Toote omadused islandi 30-01-2017
Infovoldik Infovoldik horvaadi 30-01-2017
Toote omadused Toote omadused horvaadi 30-01-2017
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 30-01-2017